Cochrane review of using Pralidoxime for organophosphate toxicity reveals insufficient evidence for or against its use. WHO recommended dose in RCT trended towards patient harm in all subgroups. Overall quality of evidence is poor. https://t.co/yD4T8S42Sn
RT @EM_vlee: Graudins: High dose pralidoxime for OP tox may not be useful https://t.co/fCOZPW4JhZ #acemvic16
RT @EM_vlee: Graudins: High dose pralidoxime for OP tox may not be useful https://t.co/fCOZPW4JhZ #acemvic16
Graudins: High dose pralidoxime for OP tox may not be useful https://t.co/fCOZPW4JhZ #acemvic16
RT @TAPNA2015: Michael Eddleston,keynote speaker at #APAMT15 https://t.co/T8QQZM9rXg oximes in OP poisoning https://t.co/kgVNjMeLAI #FOAMT…
Michael Eddleston,keynote speaker at #APAMT15 https://t.co/T8QQZM9rXg oximes in OP poisoning https://t.co/kgVNjMeLAI #FOAMTox
@umanamd Buckley et al also did the 2011 Cochrane review: http://t.co/1UxTujlxQm
@umanamd Buckley et al also did the 2011 Cochrane review: http://t.co/1UxTujlxQm